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Purpose: To observe the efficiency of reirradiation with
high dose rate intraluminal brachytherapy in  symptomatic
palliation of recurrent  endobronchial tumors. Materials and
Methods: Between January 1994 and June 1998, 21 patients
diagnosed with recurrent endobronchial tumors following
external beam radiotherapy were treated palliatively with high
dose rate intraluminal irradiation at Hacettepe University
Oncology Institute. A single fraction of 10 Gy was prescribed
to the specified area in 9 patients and 15 Gy to 12. Results:
Endobronchial treatment improved the performance and
reduced symptomatology in 17 (81%) patients. Ten dyspneic
patients (10/14, 71%) recovered clinically with an accom-
panying radiological downstaging. The median symptomatic
palliation was 45 days (range, 0 - 9 months), and the overall
median survival was 5.5 months (range, 4 - 12 months). The
palliative intrabronchial brachytherapy was well tolerated, with
the exception of in one patient with a fatal hemorrhage, and
another with medically salvaged bronchospasm and intrabron-
chial edema. Conclusion: Recurrent patients with a history of
previous thoracic external beam irradiation can be effectively
palliated with high dose rate endobronchial reirradiation if the
symptoms are directly related to the endobronchial tumor. 
Key Words: Endobronchial radiotherapy, brachytherapy,
reirradiation, lung cancer
INTRODUCTION
Lung cancer remains a major worldwide health
problem and is the leading cause of cancer
mortality in both men and women.
1 The majority
of those diagnosed have locally advanced stage III
(44%) or metastatic stage IV (32%) diseases, and
less than one quarter are potentially operable at
diagnosis.
1 Generally, 75% distant metastases and
50 - 75% local recurrence occur in stage III and
surgical resection, with consideration for post-
operative adjuvant therapy or radiation and
chemotherapy, with or without surgical resection,
are evaluated to manage the disease. Disease
progression within the irradiated field occurs in
33 to 50% of irradiated patients within 15
months.
2-4 A prominent endobronchial disease
may worsen the recurrence, with symptoms of
cough, obstruction, shortness of breath and severe
hemoptysis. The quality of life should be
improved in these patients by means of relieving
the symptoms, even with a very limited expected
survival. Recent advances in techniques, such as
laser treatment, brachytherapy, cryotherapy,
electrocautherization and intraluminal stents,
have equipped the clinician with decent palliation
modalities. Endobronchial radiotherapy is a well
known option, with minimal complications and
rapid fall off of the radiation dose, which spares
the normal surrounding tissues,
5,6 as high dose
radiation is delivered to the target. Herein, our
experience of palliative endobronchial radio-
therapy, on 21 previously irradiated recurrent
lung carcinoma patients presenting with endo-
bronchial tumors, is assessed to evaluate efficacy
of this modality.
MATERIALS AND METHODS
Twenty-one recurrent non-small cell lung carci-
noma (NSCLC) patients were treated with high
dose rate (HDR) endobronchial brachytherapy
between January 1994 and June 1998. All patients
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were admitted to our department with evidence
of recurrent endoluminal tumors and persistent
symptoms of hemoptysis, cough and dyspnea. All
patients had completed external beam thoracic
radiotherapy (EBRT) at least 4 months before this
study.
All patients had complete systemic and primary
work-ups prior to the endobronchial brachy-
therapy, including a chest X-ray, complete and
biochemical blood counts and chest/abdomen
computerized tomography. Treatments were ap-
plied on an outpatient basis. A respiratory dis-
eases specialist performed a flexible fiberoptic
bronchoscopy, under local anesthesia, to visualize
the tumor location. A hollow closed ended
polyurethane afterloading catheter (5 - 6F) was
then advanced beyond the site of the obstruction.
Double catheters were chosen only in 2 patients
due to their recurrences in carina. The position of
the catheters was verified using direct X-ray films.
The application was performed with a high dose
rate Ir-192 afterloading system (microSelectron-
Oldeft Nucletron, Netherlands). A single fraction
dose of 10 Gy was prescribed to the specified area
to 1 cm in 9 patients and 15 Gy in 12.
The initial performance was recorded by
scoring the Karnofsky Performance Status (KPS).
Patients were evaluated with the Speiser Dyspnea
Index before and after the treatment (Table 1).
7
The survival time and symptom control were
calculated from the date of initiation of the endo-
bronchial brachytherapy. Actuarial survival an-
alyses were performed using the Kaplan-Meier
method.
8
RESULTS
Our cohort consisted of 16 males and 5 females,
with a median age of 54, ranging from 32 to 70
years. The initial diagnostic staging was stage III
A in 16 and stage III B in 5 cases. Pathological
diagnosis, by an endoscopic biopsy, revealed a
squamous cell carcinoma in 18, an adenocar-
cinoma in 2 and a bronchoalveolar carcinoma in
one. The recurrent diseases, detected from bron-
choscopy, were as follows; 12 in the right main
bronchus, 6 in the left main bronchus, 2 in the
carina and 1 in the lower carina. Previous EBRT
had been applied at outside institutions in all but
4 patients, leading to different radiotherapy
protocols, with a median total conventional
equivalent dose of 30 Gy (range, 30 - 70 Gy) (Table
2). In addition to EBRT, all patients had mainly
received cisplatin based chemotherapy protocols
before their referral to our institution.
The study group had advanced stage diseases
and 5 patients (24%) had distant metastasis at the
time of admission to our institute; including 2 in
the adrenal glands, 2 in bone and 1 in the brain.
Table 1. Speiser Dyspnea Index
Symptom score Symptom evaluation
0 No dyspnea
1 Dyspnea on moderate exertion
2 Dyspnea with normal activity, walking on level ground
3 Dyspnea at rest
4 Requires supplement oxygen
Table 2. Initial External Beam Irradiation Schemas of Patients before Recurrence
Patients (n) Total dose (cGy) Daily fractions (cGy)
10 3,000 200
5 6,000 200
3 4,480 320
2 3,000 300
1 7,000 200A. Faruk Zorlu, et al.
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All 21 patients had radiologically or bronchosco-
picaly demonstrated intraluminal tumors, with
substantial constitutional symptoms at presenta-
tion, with the exception of 2 (2/21, 9.5%) asymp-
tomatic cases. Fourteen (66.7%) patients had
severe dyspnea, with evidence of obstruction and
atelectasis, which was radiologically visible in 12
(12/14, 85.7%) cases. Five patients (5/21, 24%) had
severe hemoptysis that required immediate pallia-
tion. The patients demonstrated a broad range of
performance stati at the time of the protocol initia-
tion, with a mean KPS of 60, ranging from 40 to
90.
The median interval from completion of exter-
nal irradiation to the onset of brachytherapy was
5.5 months, ranging from 4 to 12 months. Endo-
bronchial treatment improved the performance
and reduced symptomatology in 81% of cases
(17/21) (Table 3). Ten of the 14 dyspneic patients
recovered clinically, with radiological down-
staging. Durable symptoms of shortness of breath
persisted in 3 of the remaining 4 nonresponsive
cases and dyspnea progressed in one patient (Fig.
1). The hemoptysis in 5 patients recovered with
the endobronchial brachytherapy, one patient had
sudden fatal hemoptysis on the third postradio-
therapy day, which was considered a brachy-
therapy complication.
The mean period of palliation was 45 days,
ranging from 0 to 9 months. The period of pallia-
tion was significantly longer in patients with a
high KPS ( 80) at the initial evaluation (p = 0.04).
The median survival of all the patients was 5.5
months, ranging from 4 to 12 months. Improved
survival was borderline significant in cases with
a KPS 80 (p = 0.05).
No serious acute complications developed with
the brachytherapy procedure, with the exception
of 2 cases; one with fatal hemoptysis and the
second with intrabronchial edema that required
medical attention.
DISCUSSION
Endobronchial HDR radiotherapy has been easy
to apply as an outpatient procedure, with mini-
mum complication rates, and one of the modali-
ties used in the palliation of recurrent intralu-
minal tumors. Recurrent patients often present
with symptoms of cough, obstruction, shortness of
breath and severe hemoptysis. Endobronchial
radiotherapy may be the first option in eligible
recurrent lung carcinoma patients with evident
endobronchial tumors. This modality has been
observed as a reliable way of palliation in most
of our patients.
Recurrent lung carcinoma patients, treated
initially with external beam radiotherapy or
chemotherapy, are generally not within curable
limits. Therefore, palliation becomes the most
important end point when survival concerns are
absent. On the other hand, assessing the degree of
palliation and quantification of symptom relief are
not easy. Symptomatic relief was provided to 79%
of our patients (15/19), which was reasonably
comparable to other published series.
5,6,9 All
Table 3. Symptom Relief after Brachytherapy
Complaints Cases (n) Cases with relief (%)
Dyspnea 14 10 (71.4)
Hemoptysis 5 4 (80.0)
Fig. 1. Dyspnea evaluation with the Speiser Dyspnea
Index before and after brachytherapy.Endobronchial Radiotherapy in Recurrent Lung Carcinoma
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patients with hemoptysis improved with the pro-
cedure, and 71% of the dyspneic cases were
relieved. However, our median duration of pallia-
tion was only 45 days, which was briefly shorter
than in other reports, such as the 26 weeks for
Gauwitz et al, and the 4.3 months of Seagran et
al.
5,6 It was concluded that this difference in the
median duration of palliation was related with the
initial patient selection criteria, as the observed
duration of palliation was shorter if the KPS was
initially low. While patient selection is essential,
endobronchial irradiation is known to be more
effective and advantageous for survival when
primarily considered after definite external beam
irradiation.
7
Brachytherapy is known as an effective pallia-
tive method for an advanced disease, either alone
or combined with external radiotherapy, and has
been shown to be useful with mainly a single
fraction of 15 Gy.
10 Fractionated brachytherapy in
previously irradiated recurrent patients might be
an option to minimize the side effects,
11 but one
fraction with a single bronchoscopic catheter ap-
plication seems to provide lower cost and im-
proved patient comfort, without major objective
or subjective complications.
Fatal hemoptysis was experience in only one of
our cases, and massive hemorrhages following
endobronchial brachytherapy have been reported
to range from 25 to 32% in previous studies.
6,12 No
perforation was observed during endoscopy in
our subjects, which is not frequent with modern
fiberoptic bronchoscopes and flexible catheters.
Pneumonia, edema and bronchospasm may be
evident after brachytherapy,
6,12 and intrabronchial
edema with bronchospasm was experienced in
one of our patients, who was successfully medi-
cally managed. No radiation bronchitis and
stenosis was detected after the treatments, which
are frequently recognized as complications of
brachytherapy.
7,9
Local treatment modalities, such as laser ther-
apy, cryotherapy and electrocautherization, with
or without brachytherapy, are also available to
palliate symptoms of endobronchial lesions to
obtain tumor regression and relief of obliteration.
13,14 Implantation of airway prosthetic stents, for
airway potency and palliation of bronchogenic
carcinoma symptoms, has become another endo-
scopic option when extrinsic airway compression
is evident in computed tomography or bron-
choscopic evaluation for dyspnea.
15-17 Acute im-
provement of symptoms and pulmonary function
after placement of an endobronchial stent for
airway obstruction may be dramatic,
16,17 but does
not help hemoptysis. Transbronchoscopic laser
therapy is another easily applicable alternative.
18
Neodymium: yttrium-aluminum-garnet (Nd : YAG)
laser is used to resect endobronchial tumors to
relieve symptoms. The median survival time after
laser resection is about 6 months in primary
tumors.
19 However, the requirement of general
anesthesia, the increase in bleeding and anatomic
deformities and the high prices are leading obsta-
cles. Combination of palliative modalities could be
an option to extend palliation duration, but the
complication rates might also be increased.
In conclusion, it is our belief that high dose rate
endobronchial irradiation can effectively contri-
bute to individual palliation of recurrences in
previously irradiated lung carcinoma patients if
the presenting symptoms are directly related with
the endobronchial tumor lacking any aid to
relieve other possible symptoms related with the
non-endobronchial component. Accordingly, pa-
tient selection seems to be an important parameter
to accurately palliate the target patient population;
and a longer duration of palliation can only be
expected in patients with high performance
scores. The combination of brachytherapy with
other modalities, such as laser therapy or stent
application, needs to be evaluated to possibly
offer an effective and longer term palliation.
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